Avicenna Life Sci Master Fund LP - 02 Feb 2026 Form 3 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
Director, 10%+ Owner
Signature
AVICENNA LIFE SCI MASTER FUND LP, By: Avicenna Life Sci Master GP LLC, its GP By: /s/ Raymond Debbane, Name: Raymond Debbane Title: Chief Executive Officer
Issuer symbol
LXRX
Transactions as of
02 Feb 2026
Net transactions value
$0
Form type
3
Filing time
12 Feb 2026, 21:29:24 UTC
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
Avicenna Life Sci Master Fund LP Director, 10%+ Owner 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK AVICENNA LIFE SCI MASTER FUND LP, By: Avicenna Life Sci Master GP LLC, its GP By: /s/ Raymond Debbane, Name: Raymond Debbane Title: Chief Executive Officer 12 Feb 2026 0002110935
Avicenna Life Sci Master GP LLC Director, 10%+ Owner 750 LEXINGTON AVENUE 30TH FLOOR, NEW YORK AVICENNA LIFE SCI MASTER GP LLC, By: /s/ Raymond Debbane, Name: Raymond Debbane, Title: Chief Executive Officer 12 Feb 2026 0002110936

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LXRX Common Stock 1,538,462 02 Feb 2026 See Footnotes F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of common stock par value $0.001 per share (the "Common Stock") are directly held by Avicenna Life Sci Master Fund LP. The general partner of Avicenna Life Sci Master Fund LP is Avicenna Life Sci Master GP LLC. The managing member of Avicenna Life Sci Master GP LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane.
F2 Each of the Reporting Persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Remarks:

Invus Public Equities, L.P. directly holds 7,362,368 shares of Common Stock, Invus, L.P. directly owns 35,402,689 shares of Common Stock, Invus US Partners LLC directly owns 5,451,204 shares of Common Stock, Mr. Debbane directly owns 1,385,689 shares of Common Stock and Artal Participations S.a r.l. directly holds 154,734,327 shares of Common Stock, which securities are reported on a separate Form 4. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.